Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy

Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy

(2021) Xia Liu et al.   Science Translational Medicine

Acquired Resistance to Immune Checkpoint Inhibitors

(2020) Adam J. Schoenfeld et al.   CANCER CELL

The p38 Pathway: From Biology to Cancer Therapy

(2020) Adrián Martínez-Limón et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy

(2020) Xia Liu et al.   JOURNAL OF CLINICAL INVESTIGATION

T cells, aging and senescence

(2020) Luca Pangrazzi et al.   EXPERIMENTAL GERONTOLOGY

Role of DNA repair defects in predicting immunotherapy response

(2020) Jing Zhang et al.   Biomarker Research

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

(2020) Sreya Bagchi et al.   Annual Review of Pathology-Mechanisms of Disease

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

(2020) Antoni Ribas et al.   Nature Communications

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

(2019) Triparna Sen et al.   Cancer Discovery

CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer

(2019) Laura M. McLane et al.   Annual Review of Immunology

Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy

(2019) Qiang Zhang et al.   CANCER RESEARCH

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

(2019) Akintunde Akinleye et al.   Journal of Hematology & Oncology

A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer

(2019) Ignace Vergote et al.   GYNECOLOGIC ONCOLOGY

Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment

(2019) Yangjing Zhao et al.   Cellular & Molecular Immunology

T Cell Dysfunction in Cancer

(2018) Daniela S. Thommen et al.   CANCER CELL

Next generation of immune checkpoint therapy in cancer: new developments and challenges

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition

(2018) Xia Liu et al.   Nature Communications

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy

(2018) Lingyun Li et al.   Cell Metabolism

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

(2017) Alice O. Kamphorst et al.   SCIENCE

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

(2016) Peter J.R. Ebert et al.   IMMUNITY

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer

(2015) Yung-Jue Bang et al.   JOURNAL OF CLINICAL ONCOLOGY

ATM and ATR as therapeutic targets in cancer

(2015) Anika Maria Weber et al.   PHARMACOLOGY & THERAPEUTICS

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence

(2014) J. Ye et al.   EMBO Molecular Medicine

The Erk2 MAPK Regulates CD8 T Cell Proliferation and Survival

(2014) W. N. D'Souza et al.   JOURNAL OF IMMUNOLOGY

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Update on the Targeted Therapy of Melanoma

(2013) Douglas B. Johnson et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Human regulatory T cells induce T-lymphocyte senescence

(2012) J. Ye et al.   BLOOD

Lamin B1 loss is a senescence-associated biomarker

(2012) Adam Freund et al.   MOLECULAR BIOLOGY OF THE CELL

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

Targeted inhibition of IL-10-secreting CD25−Tregviap38 MAPK suppression in cancer immunotherapy

(2010) Kozo Ohkusu-Tsukada et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression

(2009) Ethan M. Shevach   IMMUNITY

Tumor-Induced Senescent T Cells with Suppressor Function: A Potential Form of Tumor Immune Evasion

(2008) C. L. Montes et al.   CANCER RESEARCH